Congratulations to Professor Naveed Sattar, who is co-author of the EMPEROR-reduced clinical trial, which featured as one of the top outputs at ESC 2020 and is published in the NJEM (New England Journal of Medicine). 

The EMPEROR-reduced trial substantially strengthens role of SGLT2i class in HF treatment paradigm which is explored further in John Jarcho’s editorial to the NJEM paper.    

First published: 2 September 2020

<< News


Read the NEJM article

Read the John Jarcho Editorial in NEJM

ESC 2020 EMPEROR-reduced Press Release